Insight Genetics, based in Nashville, Tenn., said that David Burg has joined the company as associate director of business development. Burg will lead sales and marketing for the company's Insight Molecular Labs. Prior to joining Insight, Burg was regional sales director for Response Genetics. He has also been a senior executive oncology account manager with GlaxoSmithKline.
ImmunID announced that it has appointed Bernhard Sixt to be company president and CEO, and Nicolas Pasqual, the firm's co-founder and former CEO, to be its chief scientific officer. Sixt co-founded Agendia and served as its CEO from 2003 to 2011, and he has over 25 years of experience in the development and commercialization of diagnostics, pharmaceuticals, and lab services at companies like Amersham and Nycomed.